Lycia Therapeutics was founded with the mission to revolutionize the treatment of diseases by targeting and degrading extracellular proteins. The company leverages its proprietary LYTAC (Lysosomal Targeting Chimera) platform to develop innovative therapies aimed at depleting difficult-to-drug targets. Lycia's core focus is on creating first-in-class extracellular protein degraders, addressing unmet medical needs across various therapeutic areas.
Notable affiliates include leading scientists and industry experts who contribute to the company's strategic direction and innovation. Lycia has garnered significant interest from top-tier investors, aiding in its rapid development and growth. The company's groundbreaking work with the LYTAC platform has positioned it as a leader in the field of extracellular protein degradation, promising substantial impact on future therapeutic approaches and patient outcomes.
